Jack Jumper Allergy Program, Royal Hobart Hospital, Hobart, TAS, Australia.
Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, TAS, Australia.
Clin Exp Allergy. 2018 Sep;48(9):1222-1234. doi: 10.1111/cea.13224. Epub 2018 Aug 3.
The venomous stings of Jack Jumper ant (JJA; species of the Myrmecia pilosula taxonomic group) are a significant public health issue in parts of south-eastern and south-western Australia, causing anaphylaxis in approximately 3% of the population. Three allergenic peptides, Myr p 1, Myr p 2 and Myr p 3, and one histamine-releasing peptide, pilosulin 5, have been fully described, but there are at least 5 additional high molecular weight IgE-binding components that have not been identified.
To identify IgE-binding components in JJA venom (JJAV) and to relate the IgE recognition of these components to relevant clinical parameters.
Identification of IgE-binding components and determination of their sensitizing prevalence was performed using SDS-PAGE immunoblot assay and sera from 90 patients with confirmed allergy to JJAV. Tandem mass spectrometry was used for identification of novel JJAV components fractionated by size exclusion chromatography (SEC) and SDS-PAGE.
Using SDS-PAGE immunoblot, 10 IgE-binding bands were identified in JJAV, two of which were recognized by 81% and 47% of the population studied. Mass spectrometry identified 17 novel JJAV proteins, including 2 glycoproteins, and confirmed the presence of 4 known Myr p and pilosulin peptides in JJAV. Most of the newly identified IgE-binding proteins were enzymes, including phospholipase A , hyaluronidase, arginine kinase and dipeptidyl peptidase IV. Correlations were found between recognition of certain IgE-binding bands with JJAV-specific IgE titre by ImmunoCAP, intradermal test threshold and treatment-related issues.
This study has for the first time revealed the identity of various proteins with IgE-binding capacity in the venom of JJA and demonstrated their clinical relevance in the diagnosis and treatment of JJAV allergy.
在澳大利亚东南部和西南部的部分地区，跳杰克蚁（JJA；Myrmecia pilosula 分类群的物种）的毒刺是一个严重的公共卫生问题，约有 3%的人群会对其产生过敏反应。目前已经充分描述了三种变应原性肽（Myr p 1、Myr p 2 和 Myr p 3）和一种组胺释放肽（pilosulin 5），但还有至少 5 种未被识别的额外高分子量 IgE 结合成分。
鉴定跳杰克蚁毒液（JJAV）中的 IgE 结合成分，并将这些成分的 IgE 识别与相关临床参数联系起来。
使用 SDS-PAGE 免疫印迹法和 90 名已确诊对 JJAV 过敏的患者的血清鉴定 IgE 结合成分，并确定其致敏的流行率。使用串联质谱法对通过大小排阻色谱（SEC）和 SDS-PAGE 分离的新型 JJAV 成分进行鉴定。
使用 SDS-PAGE 免疫印迹法，在 JJAV 中鉴定出 10 种 IgE 结合带，其中 2 种被研究人群的 81%和 47%识别。质谱鉴定出 17 种新型 JJAV 蛋白，包括 2 种糖蛋白，并确认 JJAV 中存在 4 种已知的 Myr p 和 pilosulin 肽。新鉴定的 IgE 结合蛋白大多数为酶，包括磷脂酶 A 、透明质酸酶、精氨酸激酶和二肽基肽酶 IV。发现某些 IgE 结合带的识别与 ImmunoCAP 测定的 JJAV 特异性 IgE 滴度、皮内试验阈值和与治疗相关的问题之间存在相关性。
本研究首次揭示了 JJA 毒液中具有 IgE 结合能力的各种蛋白质的身份，并证明了它们在 JJAV 过敏的诊断和治疗中的临床相关性。
